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Background:  Dabigatran etexilate is an oral, direct thrombin inhibitor that has shown superior efficacy to warfarin in patients with atrial 
fibrillation, without an elevated risk of bleeding. However, as with all anticoagulants, the need for an appropriate strategy to reverse anticoagulation 
is important particularly in patients that require emergency procedures or in overdose situations. The effects of a specific antibody designed to 
neutralize dabigatran activity were tested.
Methods:  Monoclonal antibodies were generated in mice immunized with dabigatran hapten. These antibodies were tested for binding affinity 
(Kd) to dabigatran and the inhibition of anticoagulant activity in functional assays (diluted thrombin time). Candidates with best affinity profiles 
were selected and underwent humanization/optimization procedures to reduce immunogenicity and maintain activity. Lead candidates were also 
expressed in Fab format to achieve a shortened in vivo half life. Selected candidates were tested for their ability to reverse the anticoagulant effect 
of dabigatran in human plasma in vitro and in rats ex vivo using diluted thrombin time.
Results:  The engineered antibody, clone 22, had a highly potent and specific Kd of 34 pM to dabigatran. This binding correlated with complete 
inhibition of dabigatran anticoagulant activity (IC50 of 2-5 nM) both in human plasma and whole blood. Nonspecific antibodies had no effect in any 
of these assay systems. Ex vivo studies demonstrated complete inhibition of anticoagulant activity of dabigatran.
Conclusions:  These data demonstrate the potent and selective reversal of dabigatran anticoagulation with an antibody targeted against 
dabigatran, without affecting normal hemostasis. This is currently under further development for use in the clinic and may result in a method that will 
allow rapid and specific reversal of dabigatran activity in patients requiring this.
